Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors. Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors

To identify signalling pathways altered by treating prostate cancer cells with the metabolic inhibitors P-SiaFNEtoc, Fucotrim I and Fucotrim II, we treated CWR22Rv1 cells with P-SiaFNEtoc, Fucotrim I and Fucotrim II for 72 hours and their respective vehicle control with DMSO. We then performed differential gene expression, Gene Ontology and GSEA analyses using data obtained from RNA-seq of the control and treated cell lines. Overall design: Comparative gene expression profiling analysis of RNA-seq data for vehicle control CWR22Rv1 cells vs CWR22Rv1 cells treated with metabolic inhibitors.